Cargando…
Efficacy and safety of lemborexant in midlife women with insomnia disorder
OBJECTIVE: Insomnia is common in midlife women. The efficacy and safety of lemborexant (LEM), a competitive dual orexin receptor antagonist, was assessed for 12 months in a subgroup of midlife women (age, 40-58 y) from Study E2006-G000-303 (Study 303; SUNRISE-2). METHODS: This was a randomized, doub...
Autores principales: | Terauchi, Masakazu, Cheng, Jocelyn Y., Yardley, Jane, Pinner, Kate, Moline, Margaret, Malhotra, Manoj, Inabe, Kanako, Nishida, Maika, Pappadopulos, Elizabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389212/ https://www.ncbi.nlm.nih.gov/pubmed/37339396 http://dx.doi.org/10.1097/GME.0000000000002209 |
Ejemplares similares
-
PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022) -
Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
por: Takaesu, Yoshikazu, et al.
Publicado: (2023) -
Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
por: Dash, Amitabh, et al.
Publicado: (2022) -
P096 Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia
por: Drake, C, et al.
Publicado: (2021) -
P097 Incidence of abnormal dreams and nightmares with lemborexant in adults with insomnia: results from two Phase 3 studies
por: Roth, T, et al.
Publicado: (2021)